MedTrace Logo

Novel MRI Techniques for Pancreatic Cancer

NCT04306861 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-07-21

No results posted yet for this study

Summary

The purpose of this study is to optimize magnetic resonance imaging (MRI) sequences for imaging pancreatic ductal adenocarcinoma and correlate MRI biomarkers with the expression of the tumor suppressor gene SMAD4 and clinical outcomes with the goal of identifying which biomarkers are predictive of treatment response or non-response. This study will test magnetic resonance techniques on FDA approved clinical MRI machines in treatment-naïve patients with biopsy-proven PDAC.

Conditions

Interventions

DIAGNOSTIC_TEST

MRI

Baseline contrast-enhanced MRI and 2 follow-up contrast-enhanced MRIs (mid-treatment and treatment completion)

Sponsors & Collaborators

Principal Investigators

  • Leo L Tsai, MD, PhD · Beth Israel Deaconess Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-09
Primary Completion
2022-08-30
Completion
2022-08-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04306861 on ClinicalTrials.gov